Pergamon

Tetrahedron Letters 39 (1998) 9715–9718

TETRAHEDRON LETTERS

Enantioselective Carbanion Cyclization of 5-Alkenyl Carbamates Induced by Asymmetric Lithiation with *s*-Butyllithium/(-)-Sparteine System

Katsuhiko Tomooka,* Nobuyuki Komine, Tomoya Sasaki, Hideo Shimizu and Takeshi Nakai*

Department of Chemical Technology, Tokyo Institute of Technology
Meguro-ku, Tokyo 152-8552, Japan

Received 14 September 1998; revised 9 October 1998; accepted 16 October 1998

Abstract: Treatment of (*E*)-6-phenyl-5-hexenyl carbamates with *s*-BuLi / (-)-sparteine is shown to afford the *trans*-1,2-disubstituted cyclopentane derivatives in high % ee, along with the bicyclo[3.1.0]hexanes (bicyclization products).

Keyword: carbanions; cyclization; enantiocontrol; lithiation

The carbanion cyclization of 5-alkenyllithiums and their hetero-analogues has emerged as an efficient method for carbocyclization.[1] Recently, this type of carbanion cyclization has been proven to proceed with complete retention of configuration at the Li-bearing carbanion center (eq. 1).[2] Thus, this stereospecificity led us to envision that, if the Li-bearing center is generated in an *enantioselective* fashion and is configurationally stable, the cyclization product could be obtained in an enantio-enriched form. To this end, we have now investigated the feasibility of an enantioselective cyclization induced by asymmetric lithiation using (-)-sparteine as an external chiral ligand. In view of the recent remarkable progress in the sparteine-based asymmetric lithiation technology,[3] 5-alkenyl carbamates were chosen as the substrates for our study. Described herein is the successful realization of the enantioselective carbanion cyclization of (*E*)-5-alkenyl carbamates (eq 2).[4,5]



(1)



(2)

First, we examined the enantioselective cyclization of 6-phenyl-5-hexenyl carbamate (**1a**, >95% *E*)[6] prepared from δ-valerolactol with Horner-Emmons olefination, followed by reaction with *N,N*-diisopropylcarbamoyl chloride (CbCl). Thus, **1a** was treated with an ethereal solution of *s*-BuLi (5 equiv.) pre-mixed with (-)-sparteine (5 equiv.)[7] at -78 ℃ for 5 hours to afford, after standard workup, the desired

0040-4039/98/$ - see front matter
PII: S0040-4039(98)02233-3

cyclopentane **2a**[8] as a single diastereomer in 47% yield, along with 27% yield of 6-phenyl-bicyclo [3.1.0]hexane **3a**[8,9] and recovered **1a** (eq 3).



The absolute stereochemistry of **2a** was assigned as (1*R*, 2*S*)-*trans* by its conversion[10] to alcohol **4a**, whose physical data (^{1}H NMR and $[\alpha]_D$) were in accord with the reported values[11] and its enantiopurity was determined to be >95% ee by ^{1}H NMR analysis of the MTPA ester of **4a**. This stereochemical outcome is rationalized as a result of the highly (*S*)-selective asymmetric lithiation[3a] forming (*S*)-**5a**, followed by the completely retentive cyclization as expected (eq 4). The formation of bicyclohexane **3a** is explained as a result of the subsequent S_N2-type cyclization of the resulting benzylic lithium **6a** which proceeds with inversion of configuration at the carbamoyloxy-carbon.[12]



Next, our attention was turned to the asymmetric cyclization of the *racemic* 4-siloxy carbamate **1b**, wherein a kinetic resolution may occur during the initial and/or subsequent cyclization. The racemic substrate **1b** (>95% *E*) was prepared from γ-butyrolactol via reaction with lithium phenyl acetylide followed by reduction with $LiAlH_4$ and protection with CbCl and TBSCl. The cyclization of **1b**, when induced with *s*-BuLi / (-)-sparteine in a similar way, was found to give cyclopentane **2b** and bicyclohexane **3b**, both as a single stereoisomer, in a nearly 1:1 ratio (eq 5).[8] The absolute configuration of **2b** was assigned as (1*R*, 2*S*, 3*S*) by its conversions to the known compounds,[13] whereas the absolute stereochemistry of **3b** was determined as (1*R*, 2*R*, 5*S*, 6*R*) by X-ray crystallography of its derivative.[14]



These stereochemical outcomes reveal that both **2b** and **3b** arise exclusively from the initial *(S)*-selective lithiation, while their siloxy-configurations (C3 for **2b** and C2 for **3b**) are opposite to each other. Therefore, it appears unlikely that any kinetic resolution occurs during the initial 5-exo-cyclization,[15] but, significantly enough, an efficient kinetic resolution *does* occur at the subsequent cyclopropane-forming cyclization stage. In other words, the benzylic lithium (3*R*)-**6b** generated via the cyclization of (*R*)-**1b** spontaneously undergoes the second cyclization leading to **3b**, whereas the benzylic lithium (*3S*)-**6b** derived from (*S*)-**1b** does only 4%, thus permitting the isolation of **2b**.[16]

Finally, we attempted to intercept the benzylic lithium species **6b** with an external electrophile. Thus, *rac*-**1b** was treated successively with (-)-sparteine / *s*-BuLi (1.5 / 3.0 equiv.)[17] and benzaldehyde (1.0 equiv.) to afford the expected adduct **7**[8] (with five contiguous chirality centers) as a major product (eq 6).[18] Of special interest is the finding that the adduct is stereochemically homogeneous as judged from ^{1}H and ^{13}C NMR spectra,[8] although the exact stereochemistry has not been determined yet.



In summary, we have demonstrated that the carbanion cyclization of (*E*)-6-phenyl-5-hexenyl carbamates, when induced with an *s*-BuLi / (-)-sparteine system, proceeds with extremely high enantioselectivity to afford the cyclopentanol derivatives, together with the rather unexpected bicyclohexane derivatives arising from the subsequent cyclopropane-forming cyclization. Work on improvement and expansion of the substrate scope of the present enantioselective cyclization methodology is in progress.

Acknowledgment: This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan, the Research for the Future Program, administered by the Japan Society for the Promotion of Science and Sumitomo Foundation.

References and Notes

1. Review on carbanion cyclization: Bailey, W. F.; Ovaska, T. V. In *Advances in Detailed Reaction Mechanisms*, Vol. 3, 1994, 251-273.
2. a) Coldham, I.; Hufton, R.; Snowden, D. J. *J. Am. Chem. Soc.* **1996**, *118*, 5322-5323. b) Tomooka, K.; Komine, N.; Nakai, T. *Tetrahedron Lett.* **1997**, *38*, 8939-8942.
3. Reviews: (a) Hoppe, D.; Hense, T. *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 2282-2316. (b) Beak, P.; Basu, A.; Gallageher , D. J.; Park, Y. S.; Thayumanavan, S. *Acc. Chem. Res.* **1996**, *29*, 552-560.
4. This work was presented at the Annual Meeting of the Chemical Society of Japan, March, 1997, Tokyo, Abstract 3G101.
5. Quite recently, Hoppe *et al.* have already reported a similar enantioselective carbanion cyclization of a (*Z*)-5-alkenyl carbamate (with different *N*-substituents) using *s*-BuLi / (-)-sparteine: Woltering, M. J.; Frölich, R.; Hoppe, D. *Angew. Chem.* **1997**, *109*, 1804-1805; *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 1764-1766.
6. Initially, we attempted the carbanion cyclization of the 5-hexenol carbamate, however, no cyclization product was obtained.
7. Note that the combined use of 1.5 equiv. of *s*-BuLi and 1.5 equiv. of (-)-sparteine gave **2a** in 13% yield.
8. All the compounds were characterized by ^{1}H ($CDCl_3$, 300 MHz), ^{13}C NMR ($CDCl_3$, 300 MHz), MS and IR. Data for selected products are as follows. **2a**: ^{1}H NMR δ 7.32-7.12(m, 5H), 4.87(ddd, *J*=6.3, 5.1, 3.9 Hz, 1H), 4.07(brs, 1H), 3.69(brs, 1H), 2.92 (dd, *J*=13.2, 4.8 Hz, 1H), 2.44(dd, *J*=13.2, 9.9 Hz, 1H), 2.27(m, 1H), 2.04(m, 1H), 1.85-1.57(m, 3H), 1.45-1.08(m, 2H), 1.19(d, *J*=6.9 Hz, 12H). ^{13}C NMR δ 155.9, 141.19, 129.0, 128.3, 125.9, 81.1, 47.3, 45.6, 39.5 31.9, 29.5, 22.3, 21.3. MS m/z: 303 (M+), $[\alpha]_D^{30}$ -26.5 (c 1.48, $CHCl_3$) **3a**: ^{1}H NMR δ 7.32-7.12(m, 5H), 1.95-1.54(m, 8H), 1.28(m, 2H). ^{13}C NMR δ 142.4, 128..3, 125.7, 125.7, 125.5, 29.6, 28.0, 28.0, 23.7. MS m/z: 158 (M+). **2b**: ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.30-7.11 (m, 5H), 4.84 (m, 1H), 3.81 (m, 1H), 2.72 (d, *J*= 6.9 Hz, 2H), 2.24 (m, 1H), 1.96 (m, 1H), 1.91-1.60 (m, 3H), 1.13 (d, *J*=6.9 Hz, 6H), 1.08 (brs, 6H), 0.85 (s, 9H), -0.05 (s, 3H), -0.09 (s, 3H). ^{13}C

NMR δ 155.5, 140.4, 129.2, 128.3, 125.9, 78.6, 76.3, 55.3, 46.0, 37.8, 33.0, 29.9, 25.9, 21.4, 18.0, -4.41, -4.87. $[\alpha]_D^{25}$ -10.2 (c 0.77, $CHCl_3$) **3b**: ^{1}H NMR δ 7.35-6.90 (m, 5H), 4.63 (td, *J*=7.7, 4.7 Hz, 1H), 2.12 (t, *J*=3.2 Hz, 1H), 1.98-1.73 (m, 2H), 1.98-1.73 (m, 2H), 1.66 (m, 1H), 1.53 (m, 1H), 1.38-1.20 (m, 1H), 0.96-0.80 (m, 1H), 0.88 (s, 9H), 0.05 (s, 6H), 0.03 (s, 3H). ^{13}C NMR δ 143.2, 128.2, 125.9, 125.2, 75.4, 34.8, 30.2, 28.3, 26.1, 25.9, 21.8, 18.3, -4.4, -4.6. MS m/z: 288 (M+) $[\alpha]_D^{27}$ 40.0 (c 1.27, $CHCl_3$) **7**: ^{1}H NMR δ 7.94-7.08 (m, 10H), 5.39 (dd, *J*= 6.0, 3.3 Hz, 1H), 5.13 (m, 1H), 4.11 (m, 2H), 3.45 (d, *J*=3.3 Hz, 1H), 3.11 (dd, *J*=7.2, 6.0 Hz, 1H), 1.25 (d, *J*=7.2 Hz, 12H), 1.03 (s, 9H) 0.25 (s, 3H), 0.21 (s, 3H). ^{13}C NMR δ 154.9, 142.4, 138.6, 130.1, 127.9, 127.8, 126.9, 126.6, 77.7, 76.7, 74.7, 55.8, 55.6, 46.0, 33.2, 30.3, 25.9, 20.7, 18.0, 3.7, 4.6. $[\alpha]_D^{26}$ -53.8 (*c* 1.11, $CHCl_3$)

9. The stereochemistry of **3a** was assigned as (1,5-*cis*, 1,6-*trans*) by ^{1}H NMR analysis: *cf.* Lit. Casey, P.; Polichnowski, W.; Shusterman, J.; Jones, R. *J. Am. Chem. Soc.* **1979**, *101*, 7282-92.
10. Recently we have found that treatment of alkyl *N,N*-diisopropyl carbamates with DIBAL in ether affords the corresponding alcohol in high yields: Unpublished results (Shimizu, H. MS Thesis, Tokyo Institute of Technology, 1997).
11. Seemayer, R.; Schneider, M. P. *Recl. Trav. Chim. Pays-Bas* **1991**, *110*, 171-174.
12. For similar cyclopropane formations in organolithium reactions, see: Paetow, M.; Kotthaus, M.; Grehl, M.; Frölich, R.; Hoppe, D. *Synlett* **1994**, 1034-1036. Krief, A.; Hobe. M.; Dumont, W.; Badaoui, E.; Guittet, E.; Evard. G. *Tetrahedron Lett.* **1992**, *33*, 3381-3384. Krief, A.; Hobe. M. *Tetrahedron Lett.* **1992**, *33*, 6527-6530, 6529-6532.
13. The stereochemistry of **2b** was determined by its conversion to alcohol **2a** and C_2 symmetrical diol **8**, as depicted below.



8

14. The stereochemistry of **3b** was determined by X-ray crystallography of its phthalate **9**. Lit. for the chiral phthalate preparation, see: Harada, N.; Nehira, T.; Soutome, T.; Hiyoshi, N.; Kido, F. *Enantiomer*, **1996**, *1*, 35. Crystal data for **9** ($C_{30}H_{33}NO_5S$): orthorhombic, $P2_12_12_1$ (#19), a=11.903(2) Å, b=19.630(10) Å, c=11.685(2) Å, V= 2730.4 Å^3, Z=4. A total of 3906 reflections ($h,k,\pm l$) were collected in the range $2\theta_{max}$ 60.1° being used in the structural refinement by full-matrix least-squares techniques (334 variables) using the TEXSAN crystallographic package from Molecular Structures Corporation Final R=0.053, R_w=0.052 (Fig.1).



9



Fig. 1 ORTEP representation of **9**

15. Quite recently, Hoppe's group has reported that an appreciable level of kinetic resolution is not observed in the *s*-BuLi / (-)-sparteine-induced cyclization of a 4-substituted 5-hexynyl carbamate: Oestreich, M.; Fröhlich, R.; Hoppe, D. *Tetrahedron Lett.* **1998**, *39*, 1745-1748.
16. The exact origin of the observed kinetic resolution is not clear at present. A possible explanation is that conformer **i** sterically preferred for the benzylic lithium (3*S*)-**6b** is not capable of the S_N2-type cyclization, whereas conformer **i v** preferred for (3*R*)-**6b** is well suited for the cyclopropane formation.



17. It is worth noting that, the yield and stereopurity of **7** were highly dependent on the amounts of (-)-sparteine and *s*-BuLi.
18. Similar 5-exo cyclization / substitution reaction was reported by Hoppe's group: see ref. 5.